Discover, develop, and deliver medicines for rare diseases, focusing on areas with high unmet medical needs. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 20% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 7.2× for every dollar of annual revenue.
Analysts' average target sits 3% above today's price.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 20% a year on average.
The company sells $634.2M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $27.1M against $634.2M in annual sales.
Over the last 12 months, executives reported 143 sells against just 9 buys. Not an alarm bell by itself, but a number worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.